Navigation Links
Precision Therapeutics Adds 8 Million Covered Lives Under Contract
Date:4/8/2008

PITTSBURGH, April 8, 2008 /PRNewswire/ -- Precision Therapeutics Inc., a leader in personalized medicine, said today it signed contracts with National Preferred Provider Network (NPPN), PlanCare America (PCA), RMSCO, and SEIBA Inc.

NPPN, headquartered in Middletown, NY, is one of the largest PPO networks in the country representing more than seven million lives. Their list of clients includes multi-state companies, Fortune 500 companies, federal organizations, and regional employers. NPPN providers include Memorial Sloan-Kettering Cancer Center, North Shore Health Systems in New York, Quest Diagnostics and Brown and Toland in San Francisco.

PCA, located in Atlanta, GA, is a national network of healthcare providers representing over a million lives. Their panel of directly contracted providers includes independent physicians, medical group practices, specialty facilities, acute care hospitals, and ancillary medical providers. PCA has relationships with over 300 payors and 12,000 employers nationwide. Payors include Taft Hartley Funds, Self Funded Groups, Insurance Companies, Third Party Administrators, and HMOs.

SIEBA, LTD, located in Endicott, NY, links the delivery of services to the employer community in the Northeast Region of the US. SIEBA's focus is providing unparalleled third party administrative services for employee benefits in both public and private sectors in the Northeast.

Established in 1981, RMSCO is now one of the largest multi-line Third-Party Administrators in the Northeast. RMSCO, headquartered in Liverpool, NY provides services to over 200 clients representing over 200,000 individuals in all 50 states.

"Precision Therapeutics is pleased to add these organizations to our growing list of payor organizations under contract. Contracting with these leading organizations expands the number of covered lives, thus allowing our technology to be available to more patients and allowing for faster reimbursement of claims," said Precision CEO Sean McDonald.

About Precision Therapeutics

Precision Therapeutics is a diagnostics services company dedicated to providing physicians, patients, and payors with information to personalize cancer treatment. Precision's ChemoFx(R) test, based on a proprietary live tumor cell-based platform, measures an individual patient's tumor sensitivity and resistance to a clinically relevant range of therapeutic alternatives under consideration by the physician. Since introduction, over 5,000 ChemoFx tests have been performed commercially in over 30 different types of solid tumors. For more information visit http://www.precisiontherapeutics.com, call 800-547-6165 or email info@ptilabs.com.


'/>"/>
SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
2. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
3. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
4. Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
6. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot ... team of professional staff discussed strategies for preventing outbreaks among camp communities during ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all ... February 8-10. , This event was exclusive to providers and offered an opportunity ... meeting took place at the Manchester Grand Hyatt where attendees gathered for a lively ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology: